Peter Hess was a reporter for Spectrum from 2019 to 2023, where he covered cannabinoids, autism prevalence, social hormones and other topics. Before joining Spectrum in 2019, he was associate science editor at Inverse, where he wrote and edited stories for a broad audience on a wide range of scientific topics, including drugs, evolution and environmental science. His work has also appeared in The Washington Post, New Scientist, Popular Science and Motherboard. Peter has an M.A. in science journalism from New York University’s Science, Health and Environmental Reporting Program. Find him on Twitter at @PeterNHess.
Peter Hess
Former news writer
Spectrum
From this contributor
Capturing autism’s sleep problems with devices nearable and wearable
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
Capturing autism’s sleep problems with devices nearable and wearable
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
Swings and misses with Jeremy Veenstra-VanderWeele
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
Ruth Carper: Imaging the aging brain in autistic adults
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
Ruth Carper: Imaging the aging brain in autistic adults
Autism-related genes converge on microglia and dopamine in zebrafish
The findings add to the growing evidence that genes with disparate functions can play similar roles in brain development.
Autism-related genes converge on microglia and dopamine in zebrafish
Explore more from The Transmitter
Personalized medicine; astroglia organoids; fast track for fragile X drug
Here is a roundup of autism-related news and research spotted around the web for the week of 20 January.
Personalized medicine; astroglia organoids; fast track for fragile X drug
Here is a roundup of autism-related news and research spotted around the web for the week of 20 January.
Neuroscientists need to do better at explaining basic mental health research
The knowledge gap between scientists, health-care professionals, policymakers and people with mental health conditions is growing, slowing the translation of basic science to new treatments. Like lawyers learning to present a case to the court, scientists should learn to educate nonscientists about their findings.
Neuroscientists need to do better at explaining basic mental health research
The knowledge gap between scientists, health-care professionals, policymakers and people with mental health conditions is growing, slowing the translation of basic science to new treatments. Like lawyers learning to present a case to the court, scientists should learn to educate nonscientists about their findings.
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.